Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasms by Site 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 4pembrolizumab 3selpercatinib 2pralsetinib 2Pemetrexed 2Paclitaxel 2Fulvestrant 2Carboplatin 2trametinib 1ribociclib 1repotrectinib 1patritumab 1palbociclib 1golotimod 1exemestane 1dabrafenib 1cobimetinib 1alectinib 1abemaciclib 1Vemurafenib 1Taxes 1Tamoxifen 1STX-478 1Radiotherapy, Intensity-Modulated 1Nimorazole 1Metformin 1Letrozole 1Imlunestrant 1Gemcitabine 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × patritumab × Head & Neck × Clear all
NCT02633800 2019-01-07

Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

Daiichi Sankyo

Phase 2 Terminated
87 enrolled 13 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡